Outlook Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Outlook Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2019 | $8.15M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $3.09M | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | $3.81M | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | $2.98M | Dec 29, 2017 |
| FY2016 | Sep 30, 2015 | $5.22M | Dec 29, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.41M | Dec 19, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $57.2K | Dec 19, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($62.42M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($75.37M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | ($58.98M) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | ($66.05M) | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | ($53.16M) | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | ($35.24M) | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | ($34.52M) | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | ($30.09M) | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | ($38.85M) | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | ($53.30M) | Dec 29, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($67.06M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($71.70M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | ($53.13M) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | ($63.07M) | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | ($51.73M) | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | ($36.84M) | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | ($36.30M) | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | ($29.64M) | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | ($35.88M) | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | ($51.35M) | Dec 29, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $27.18M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $41.76M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $26.45M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $42.33M | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | $38.96M | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | $26.34M | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | $23.81M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $18.50M | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | $23.81M | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | $32.76M | Dec 29, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $39.94M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $29.94M | Dec 19, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($51.83M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($68.79M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | ($42.97M) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | ($56.67M) | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | ($54.25M) | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | ($31.79M) | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | ($32.29M) | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | ($33.04M) | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | ($15.51M) | Dec 18, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2019 | $437.3K | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $2.78M | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | $292.1K | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | $1.10M | Dec 29, 2017 |
| FY2016 | Sep 30, 2015 | $8.80M | Dec 29, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $18.58M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $28.82M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $32.30M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $28.53M | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | $22.81M | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | $19.73M | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | $17.13M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $22.28M | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | $20.73M | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | $25.41M | Dec 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $50.77M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $101.90M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $46.74M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $19.79M | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | $18.20M | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | $16.91M | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | $27.90M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $43.09M | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | $51.46M | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | $30.58M | Dec 29, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($32.19M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($73.08M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2023 | ($14.44M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2022 | $8.74M | Dec 27, 2024 |
| FY2023 | Sep 30, 2021 | $4.61M | Dec 22, 2023 |
| FY2022 | Sep 30, 2020 | $2.83M | Dec 29, 2022 |
| FY2021 | Sep 30, 2019 | ($16.13M) | Dec 23, 2021 |
| FY2020 | Sep 30, 2018 | ($25.54M) | Dec 23, 2020 |
| FY2018 | Sep 30, 2017 | ($33.65M) | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | ($5.17M) | Dec 29, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($605.71M) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | ($543.28M) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | ($467.92M) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | ($408.94M) | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | ($342.88M) | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | ($289.72M) | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | ($254.48M) | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | ($216.31M) | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | ($186.22M) | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | ($147.37M) | Dec 29, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.08M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | $14.93M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | $23.39M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | $17.40M | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | $14.48M | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | $12.54M | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | $8.02M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | $1.72M | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | $3.19M | Dec 18, 2018 |
| FY2018 | Sep 30, 2016 | $2.35M | Dec 18, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | $1.08M | Dec 19, 2019 |
| FY2019 | Sep 30, 2018 | $165.0K | Dec 19, 2019 |
| FY2017 | Sep 30, 2017 | $203.7K | Dec 29, 2017 |
| FY2016 | Sep 30, 2016 | $2.88M | Dec 29, 2016 |
| FY2016 | Sep 30, 2015 | $2.92M | Dec 29, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | (4) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | (4) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 23, 2021 |
| FY2018 | Sep 30, 2018 | (1) | Dec 18, 2018 |
| FY2018 | Sep 30, 2017 | (1) | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | (3) | Dec 29, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | (4) | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | (4) | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Dec 23, 2021 |
| FY2018 | Sep 30, 2018 | (1) | Dec 18, 2018 |
| FY2018 | Sep 30, 2017 | (1) | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | (3) | Dec 29, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 53.89M | Dec 19, 2025 |
| FY2025 | Sep 30, 2024 | 23.91M | Dec 19, 2025 |
| FY2024 | Sep 30, 2023 | 13.01M | Dec 27, 2024 |
| FY2023 | Sep 30, 2022 | 227.31M | Dec 22, 2023 |
| FY2022 | Sep 30, 2021 | 176.46M | Dec 29, 2022 |
| FY2021 | Sep 30, 2020 | 127.18M | Dec 23, 2021 |
| FY2020 | Sep 30, 2019 | 28.61M | Dec 23, 2020 |
| FY2019 | Sep 30, 2018 | 9.03M | Dec 19, 2019 |
| FY2018 | Sep 30, 2017 | 24.93M | Dec 18, 2018 |
| FY2017 | Sep 30, 2016 | 22.80M | Dec 29, 2017 |